Literature DB >> 9562190

Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose.

K Wanger1, L Brough, I Macmillan, J Goulding, I MacPhail, J M Christenson.   

Abstract

OBJECTIVE: To determine whether naloxone administered i.v. to out-of-hospital patients with suspected opioid overdose would have a more rapid therapeutic onset than naloxone given subcutaneously (s.q.).
METHODS: A prospective, sequential, observational cohort study of 196 consecutive patients with suspected opioid overdose was conducted in an urban out-of-hospital setting, comparing time intervals from arrival at the patient's side to development of a respiratory rate > or =10 breaths/min, and durations of bag-valve-mask ventilation. Subjects received either naloxone 0.4 mg i.v. (n = 74) or naloxone 0.8 mg s.q. (n = 122), for respiratory depression of <10 breaths/min.
RESULTS: Mean interval from crew arrival to respiratory rate > or =10 breaths/min was 9.3 +/- 4.2 min for the i.v. group vs 9.6 +/- 4.58 min for the s.q. group (95% CI of the difference -1.55, 1.00). Mean duration of bag-valve-mask ventilation was 8.1 +/- 6.0 min for the i.v. group vs 9.1 +/- 4.8 min for the s.q. group. Cost of materials for administering naloxone 0.4 mg i.v. was $12.30/patient, compared with $10.70/patient for naloxone 0.8 mg s.q.
CONCLUSION: There was no clinical difference in the time interval to respiratory rate > or =10 breaths/min between naloxone 0.8 mg s.q. and naloxone 0.4 mg i.v. for the out-of-hospital management of patients with suspected opioid overdose. The slower rate of absorption via the s.q. route was offset by the delay in establishing an i.v.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562190     DOI: 10.1111/j.1553-2712.1998.tb02707.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  20 in total

1.  Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes.

Authors:  K Dettmer; B Saunders; J Strang
Journal:  BMJ       Date:  2001-04-14

2.  Battling opiate overdoses.

Authors:  D J Doyle
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

Review 3.  Strategies for preventing heroin overdose.

Authors:  Karl A Sporer
Journal:  BMJ       Date:  2003-02-22

Review 4.  Naloxone in opioid poisoning: walking the tightrope.

Authors:  S F J Clarke; P I Dargan; A L Jones
Journal:  Emerg Med J       Date:  2005-09       Impact factor: 2.740

Review 5.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

6.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

Review 7.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

8.  Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose.

Authors:  Bahar Dhowan; Jongcheon Lim; Michael D MacLean; Alycia G Berman; Min Ku Kim; Qi Yang; Jacqueline Linnes; Chi Hwan Lee; Craig J Goergen; Hyowon Lee
Journal:  J Control Release       Date:  2019-05-31       Impact factor: 9.776

Review 9.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

10.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.